Rigel Pharmaceuticals
Rigel Pharmaceuticals
Explore linked clinical trials.13 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations | IDH1-Mutated Malignancies; Mutations; Targeted Therapy | Recruiting | Phase 2 | 2026-10-05 | NCT07032727 | |
| A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia. | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm | Recruiting | Phase 2 | 2026-09-11 | NCT06566742 | |
| Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 2 | 2026-09-02 | NCT07471841 | |
| Study of Olutasidenib and Temozolomide in HGG | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, anaplastic astrocytoma, astrocytoma (excluding glioblastoma), brain disorder, brainstem cancer, central nervous system cancer, central nervous system disorder, diffuse intrinsic pontine glioma, diffuse midline glioma, H3 K27M-mutant, epithelial neoplasm, glioblastoma, glioma, grade III glioma, malignant glioma, neoplasm, nervous system disorder, neuroepithelial neoplasm, oligodendroglioma, primitive neuroectodermal tumor, spinal cord disorder, spinal cord neoplasm | Recruiting | Phase 2 | 2026-09-01 | NCT06161974 | |
| Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, acute myeloid leukemia, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, glioma, hematologic disorder, leukemia, myeloid leukemia, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 4 | 2026-08-11 | NCT07486713 | |
| Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors | Head and Neck Neoplasms, Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, endocrine system disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, thyroid gland disorder, thyroid tumor | Recruiting | Phase 4 | 2026-08-10 | NCT07704658 | |
| Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) | Hemic and Lymphatic Diseases, bone marrow disorder, hematologic disorder, myelodysplastic syndrome | Recruiting | Phase 1 / Phase 2 | 2026-08-10 | NCT05308264 | |
| Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 2 | 2026-04-16 | NCT06782542 | |
| Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 1 | 2026-04-07 | NCT06639724 | |
| Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2026-02-06 | NCT07130695 | |
| Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults | Respiration Disorders, adult acute respiratory distress syndrome, lung disorder, respiratory system disorder | Not yet recruiting | Phase 2 | 2026-02-02 | NCT06564207 | |
| Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD | Bronchiolitis Obliterans, bronchial disorder, bronchiolitis, bronchiolitis obliterans syndrome, bronchitis, cryptogenic organizing pneumonia, graft versus host disease, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 1 | 2026-01-22 | NCT06233110 | |
| A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia | Warm Antibody Autoimmune Hemolytic Anemia | Enrolling by invitation | Phase 3 | 2022-03-17 | NCT04138927 |